Abstract
dc:descriptionBackground: Mast cells are derived from the haemopoietic progenitor cell and are scattered all over the human organism especially to the physical boundaries between the organism and the environment (i.e. skin, mucosa etc). They produce after intrinsic or extrinsic stimuli a variety of mediators involved in tissue regeneration, homeostasis, angiogenesis and the immunological response and defense. In tumor environment MCs are attracted from agents secreted by the tumor and help to its growth through immunocompromise, secretion of pre-angiogenic and mitogenic factors. Alternatively these cells have antineoplastic action through secretion of cell cycle inhibitors, apoptosis, decrease of cell movement and enhancement of antineoplastic inflammation. In haematological malignancies MCs may be derived from the neoplastic clone (i.e. myeloproliferative disorders) or as a reactive response to the neoplasm. Myelodysplastic syndromes are heterogeneous group of clonal disorders of blood with common characteristics the presence of dysplastic haemopoietic cells, ineffective haematopoiesis and frequent evolution to acute leukemia. There are few publications on MCs in MDS with contradictory results Aim: Study of the role of MCs in Myelodysplastic syndromes. Patients: Seventy-three patients (37 females and 36 males) with MDS were involved in the study. Median age of females was 69 years (range 59-81) and of males 72 years (range 35-86). Twenty-one of them had refractory anaemia (MDS-RA), 18 had refractory anaemia with excess of blasts (RAEB), 18 had refractory anaemia with excess of blasts in transformation (RAEB-T), and 16 refractory anaemia with ringed sideroblasts (MDS-RARS). In the study 60 normal individuals were also included (median age 74 years and range 56-90) 32 males 28 females. Methods: The number of MCs were calculated in BM after toluidine blue staining according to classical techniques.The number of CD34(+) cells were measured with immunofluorescence with the use of anti - CD34 moAb (K567-FITC). The expression of tryptase and chymase were studied in MCs using immunocytochemistry and PAP commercial kit and each cell was graded in a scale of 0-4(+). The score was calculated as the mean value in 200 consecutive cells. The levels of tryptase and chymase in serum were measured using ELISA commercial kits. Microvascular density (MVD) was the mean value of microvessel number/0.0625mm2 field area. Endothelial cells were CD34 (+) using anti-CD34 moAb-QBEND 10 and Biogenex avidin-streptavidin kit, and had characteristic morphology . Results: Statistically higher percentage of MC in MDS (5,767±3,45%) were found compared to the normals (1,82±0,93%) (p<0.01). Especially in MDS-RA it was 4,38±1,16% , in MDS-RARS 2,18±0,75, in low/int-1 3,43±1,48 and in high/int-2 8,16±3,26. These values were statistically higher compared to the normals (p<0.01) except MDS-RARS, which did not differ from the normals(p>0.05).The tryptase expression score in high/int-2 was significantly higher compared to that in low/int-1 and normals (p<0.01) while there was no difference between low/int-1 and normals (p>0.05). The chymase expression score did not differ significantly between the above groups. In serum chymase was not detectable in any group of patients. Serum tryptase was significantly higher in MDS (40,96±35,4) compared to the normals (7,8±3,21)(p<0.01). In high/int-1 tryptase levels were 73,31±20,87 significantly higher than low/int-1 (9,48±4,217) and the normals (p<0.01). There was no significant difference in tryptase levels between normals, MDS-RA, MDS-RARS and low/int-1(p.0,05). There was positive correlation between percentage of MCs and CD34(+) cells (R2= 0,4361) as well as serum tryptase levels (R2=0,6837) in patients. Dysplastic MCs were not indentified. The MVD (microvessel number/0.0625 mm2) in the entire group of MDS was 6.3±3.3 and was significantly higher than the normals (2.23±0.38, p<0.01). In high/intermediate-2 the MVD was 7.89±2.8, in low/intermediate-1 it was 4.8±2.2, in MDS-RA it was 4.98±1.8, and in MDS-RARS it was 5±2.0. There was a significantly higher MVD in high/intermediate-2 compared to low/intermediate-1, MDS-RA, MDS-RARS and normal (p<0.01). There was also a significant difference between low/intermediate-1, MDS-RA, MDS-RARS and normals (p<0.01). There was a positive correlation between BMMC and MVD. Conclusions: MCs in BM were increased in MDS patients compared to the normal individuals. The levels of serum tryptase correlated positively with the number of BMMC raising the possibility that the tryptase was mainly produced by BMMCs and not the peripheral MCs. The number of MCs correlated positively with CD34(+) that were increased in high/int-2 MDS and consequently the advanced stages of the disease. BMMCs were positive for tryptase only and not chymase in contrast to what usually happens in reactive mastocytosis. We found increased MVD in MDS compared to the normals. We also found higher MVD in high/intermediate-2 risk MDS compared to the low/intermediate-1, in contrast to a previous study. The MVD is positively correlated with the number of BMMC. This raises the suggestion that BMMCs may contribute to tumor progression by enhancing angiogenesis.The heterogeneity of the MDS group may be responsible for the contradictory results in the literature. In order to further discriminate the role of MCs in these syndromes serial measurements should be done in the same patient during the disease progress as well as cytogenetic studies and MC cultures.
Degree
thesis:*- Grantor dc:publisher
- University of Thessaly (UTH)
- Year dc:date
- 2022
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Karras, Georgios
- Καρράς, Γεώργιος
Subjects
dc:subject × 20- Μαστοκύτταρα
- Μυελοδυσπλαστικά σύνδρομα (ΜΔΣ)
- Αγγειογένεση και νεοαγγείωση
- Ανθεκτική αναιμία
- CD34+ κύτταρα
- Τρυπτάση
- Μικροπεριβάλλον μυελού των οστών
- Mast cells
- Myelodyoplastic syndromes (MDS)
- Angiogenesis
- Refractory anaemia
- CD34+ cells
- Tryptase
- Bone marow microenvironment
- Κλινική Ιατρική
- Ιατρική και Επιστήμες Υγείας
- Κλινική ιατρική, άλλοι τομείς
- Clinical Medicine
- Medical and Health Sciences
- Clinical medicine, miscellaneous
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/52837